Herbert A A, Kidd E J, Broadley K J
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, South Wales, UK.
Br J Pharmacol. 2008 Oct;155(4):525-34. doi: 10.1038/bjp.2008.286. Epub 2008 Jul 7.
The dietary trace amines tyramine and beta-phenylethylamine (beta-PEA) can increase blood pressure. However, the mechanisms involved in the vascular effect of trace amines have not been fully established. The purpose of this study was to evaluate whether trace amine-dependent vasoconstriction was brought about by tyramine and beta-PEA acting as indirect sympathomimetic agents, as previously assumed, or whether trace amine-dependent vasoconstriction could be mediated by recently discovered trace amine-associated (TAA) receptors.
The responses to p-tyramine and beta-PEA were investigated in vitro in rings of the left anterior descending coronary arteries of pigs.
p-Tyramine induced a concentration-dependent (0.1-3 mM) vasoconstriction. The maximum response and pD(2) value for p-tyramine was unaffected by endothelium removal or pre-treatment with antagonists for adrenoceptors, histamine, dopamine or 5-HT receptors. beta-PEA also produced a concentration-dependent (0.3-10 mM) vasoconstriction which was unaffected by endothelium removal, beta-adrenoceptor or 5-HT receptor antagonists. A substantial, but reduced, response to beta-PEA was obtained in the presence of prazosin (alpha(1)-adrenoceptor antagonist), haloperidol (D(2)/D(3) dopamine receptor antagonist) or mepyramine (H(1) histamine receptor antagonist). The pD(2) value for beta-PEA was unaffected by any of the antagonists tested.
Vasoconstriction induced by p-tyramine does not involve an indirect sympathomimetic effect, although vasoconstriction caused by beta-PEA may occur, in part, by this mechanism. We therefore propose that trace amine-dependent vasoconstriction is mediated by phenylethylamine-specific receptors, which are closely related to or identical to TAA receptors. These receptors could provide a target for new antihypertensive therapies.
膳食中的痕量胺酪胺和β-苯乙胺(β-PEA)可升高血压。然而,痕量胺血管效应所涉及的机制尚未完全明确。本研究的目的是评估痕量胺依赖性血管收缩是如先前假设的那样由酪胺和β-PEA作为间接拟交感神经药起作用引起的,还是痕量胺依赖性血管收缩可由最近发现的痕量胺相关(TAA)受体介导。
在猪左前降支冠状动脉环中体外研究对对酪胺和β-PEA的反应。
对酪胺诱导浓度依赖性(0.1 - 3 mM)血管收缩。对酪胺的最大反应和pD(2)值不受内皮去除或用肾上腺素能受体、组胺、多巴胺或5 - HT受体拮抗剂预处理的影响。β-PEA也产生浓度依赖性(0.3 - 10 mM)血管收缩,且不受内皮去除、β-肾上腺素能受体或5 - HT受体拮抗剂的影响。在存在哌唑嗪(α(1)-肾上腺素能受体拮抗剂)、氟哌啶醇(D(2)/D(3)多巴胺受体拮抗剂)或美吡拉敏(H(1)组胺受体拮抗剂)的情况下,对β-PEA获得了显著但降低的反应。β-PEA的pD(2)值不受所测试的任何拮抗剂的影响。
对酪胺诱导的血管收缩不涉及间接拟交感神经效应,尽管β-PEA引起的血管收缩可能部分通过该机制发生。因此,我们提出痕量胺依赖性血管收缩由苯乙胺特异性受体介导,这些受体与TAA受体密切相关或相同。这些受体可为新的抗高血压治疗提供靶点。